Bhageria Industries Limited has submitted to the Exchange, the financial results for the period ended March 31, 2025.
BHAGERIA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Bhageria Industries reported strong FY25 results with standalone revenue from operations rising to Rs. 59,715.90 lakhs from Rs. 49,496.88 lakhs in FY24, a growth of about 20.6%. Standalone profit after tax more than doubled to Rs. 4,226.54 lakhs from Rs. 1,962.40 lakhs, with EPS at Rs. 9.68 vs Rs. 4.50. Consolidated PAT grew to Rs. 3,869.06 lakhs from Rs. 1,852.82 lakhs. The Chemical segment was the key growth driver, with segment profit jumping to Rs. 5,646.10 lakhs from Rs. 1,144.46 lakhs, though the Pharma segment widened its loss to Rs. 563.52 lakhs. The board recommended a dividend of Rs. 1.50 per share (30%) and appointed new Secretarial, Internal, and Cost Auditors. The statutory auditors issued an unmodified (clean) opinion.
Strong double-digit revenue growth and over 100% jump in profits signal a robust year for shareholders, supported by a healthy dividend. The stock may see a positive reaction, though continued losses in the Pharma segment remain a point to watch.